Zynerba Pharmaceuticals Reports First Quarter 2018 Financial Results and Operational Highlights

Pharmaceutical Investing

Zynerba Pharmaceuticals (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare neurological and psychiatric disorders with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2018 and provided an overview of recent operational highlights. As quoted in the press …

Zynerba Pharmaceuticals (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare neurological and psychiatric disorders with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2018 and provided an overview of recent operational highlights.

As quoted in the press release:

“We have made significant progress on advancing our lead asset, ZYN002 transdermal CBD gel, in the first few months of 2018,” said Armando Anido, Chairman and Chief Executive Officer of Zynerba. “We recently initiated our Phase 2 study of ZYN002 in patients with developmental and epileptic encephalopathies and we are preparing to initiate a single pivotal trial for Fragile X syndrome. We also presented important new data from our ongoing STAR 2 open label extension study in adult refractory focal seizures that continue to suggest that focal seizures may be reduced with longer-term use of ZYN002. We expect to achieve a number of additional milestones this year, which should position us for an exciting and data-rich 2018 and 2019.”

Click here to read the full press release.

The Conversation (0)
×